Eirik Ikdahl1, Silvia Rollefstad2, Grunde Wibetoe2, Inge C Olsen2, Inger-Jorid Berg2, Jonny Hisdal2, Till Uhlig2, Glenn Haugeberg2, Tore K Kvien2, Sella A Provan2, Anne Grete Semb2. 1. From the Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; Section of Vascular Investigations, Oslo University Hospital Aker; National Resource Centre for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Martina Hansens Hospital, Bærum; Division of Rheumatology, Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.E. Ikdahl, MD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; S. Rollefstad, MD, PhD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; G. Wibetoe, MD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; I.C. Olsen, PhD, Department of Rheumatology, Diakonhjemmet Hospital; I.J. Berg, MD, Department of Rheumatology, Diakonhjemmet Hospital; J. Hisdal, DrPhilos, Section of Vascular Investigations, Oslo University Hospital Aker; T. Uhlig, MD, Professor, National Resource Centre for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital; G. Haugeberg, MD, Professor, Martina Hansens Hospital, and Division of Rheumatology, Department of Neuroscience, Norwegian University of Science and Technology; T.K. Kvien, MD, Professor, Department of Rheumatology, Diakonhjemmet Hospital; S.A. Provan, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; A.G. Semb, MD, PhD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital. eirik.ikdahl@medisin.uio.no. 2. From the Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; Section of Vascular Investigations, Oslo University Hospital Aker; National Resource Centre for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo; Martina Hansens Hospital, Bærum; Division of Rheumatology, Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.E. Ikdahl, MD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; S. Rollefstad, MD, PhD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; G. Wibetoe, MD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital; I.C. Olsen, PhD, Department of Rheumatology, Diakonhjemmet Hospital; I.J. Berg, MD, Department of Rheumatology, Diakonhjemmet Hospital; J. Hisdal, DrPhilos, Section of Vascular Investigations, Oslo University Hospital Aker; T. Uhlig, MD, Professor, National Resource Centre for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital; G. Haugeberg, MD, Professor, Martina Hansens Hospital, and Division of Rheumatology, Department of Neuroscience, Norwegian University of Science and Technology; T.K. Kvien, MD, Professor, Department of Rheumatology, Diakonhjemmet Hospital; S.A. Provan, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; A.G. Semb, MD, PhD, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital.
Abstract
OBJECTIVE: We evaluated the predictive value of these vascular biomarkers for cardiovascular disease (CVD) events in patients with rheumatoid arthritis (RA): aortic pulse wave velocity (aPWV), augmentation index (AIx), carotid intima-media thickness (cIMT), and carotid plaques (CP). They are often used as risk markers for CVD. METHODS: In 2007, 138 patients with RA underwent clinical examination, laboratory tests, blood pressure testing, and vascular biomarker measurements. Occurrence of CVD events was recorded in 2013. Predictive values were assessed in Kaplan-Meier plots, log-rank, and crude and adjusted Cox proportional hazard (PH) regression analyses. RESULTS: Baseline median age and disease duration was 59.0 years and 17.0 years, respectively, and 76.1% were women. CVD events occurred in 10 patients (7.2%) during a mean followup of 5.4 years. Compared with patients with low aPWV, AIx, cIMT, and without CP, patients with high aPWV (p < 0.001), high AIx (p = 0.04), high cIMT (p = 0.01), and CP (p < 0.005) at baseline experienced more CVD events. In crude Cox PH regression analyses, aPWV (p < 0.001), cIMT (p < 0.001), age (p = 0.01), statin (p = 0.01), and corticosteroid use (p = 0.01) were predictive of CVD events, while AIx was nonsignificant (p = 0.19). The Cox PH regression estimates for vascular biomarkers were not significantly altered when adjusting individually for demographic variables, traditional CVD risk factors, RA disease-related variables, or medication. All patients who developed CVD had CP at baseline. CONCLUSION: CP, aPWV, and cIMT were predictive of CVD events in this cohort of patients with RA. Future studies are warranted to examine the additive value of arterial stiffness and carotid atherosclerosis markers in CVD risk algorithms. Regional Ethical Committee approval numbers 2009/1582 and 2009/1583.
OBJECTIVE: We evaluated the predictive value of these vascular biomarkers for cardiovascular disease (CVD) events in patients with rheumatoid arthritis (RA): aortic pulse wave velocity (aPWV), augmentation index (AIx), carotid intima-media thickness (cIMT), and carotid plaques (CP). They are often used as risk markers for CVD. METHODS: In 2007, 138 patients with RA underwent clinical examination, laboratory tests, blood pressure testing, and vascular biomarker measurements. Occurrence of CVD events was recorded in 2013. Predictive values were assessed in Kaplan-Meier plots, log-rank, and crude and adjusted Cox proportional hazard (PH) regression analyses. RESULTS: Baseline median age and disease duration was 59.0 years and 17.0 years, respectively, and 76.1% were women. CVD events occurred in 10 patients (7.2%) during a mean followup of 5.4 years. Compared with patients with low aPWV, AIx, cIMT, and without CP, patients with high aPWV (p < 0.001), high AIx (p = 0.04), high cIMT (p = 0.01), and CP (p < 0.005) at baseline experienced more CVD events. In crude Cox PH regression analyses, aPWV (p < 0.001), cIMT (p < 0.001), age (p = 0.01), statin (p = 0.01), and corticosteroid use (p = 0.01) were predictive of CVD events, while AIx was nonsignificant (p = 0.19). The Cox PH regression estimates for vascular biomarkers were not significantly altered when adjusting individually for demographic variables, traditional CVD risk factors, RA disease-related variables, or medication. All patients who developed CVD had CP at baseline. CONCLUSION: CP, aPWV, and cIMT were predictive of CVD events in this cohort of patients with RA. Future studies are warranted to examine the additive value of arterial stiffness and carotid atherosclerosis markers in CVD risk algorithms. Regional Ethical Committee approval numbers 2009/1582 and 2009/1583.
Authors: Sulé Gunter; Chanel Robinson; Gavin R Norton; Angela J Woodiwiss; Linda Tsang; Aletta M E Millen; Patrick H Dessein Journal: Clin Rheumatol Date: 2018-02-08 Impact factor: 2.980
Authors: M Robustillo-Villarino; J J Alegre-Sancho; E Rodilla-Sala; A Corrales; J Llorca; M A Gonzalez-Gay; P H Dessein Journal: Clin Rheumatol Date: 2017-05-25 Impact factor: 2.980
Authors: Fabiola Atzeni; Marco Corda; Luigi Gianturco; Maurizio Porcu; Piercarlo Sarzi-Puttini; Maurizio Turiel Journal: Front Med (Lausanne) Date: 2018-02-14